QTRX

Quanterix Corporation (NASDAQ:QTRX) is a life sciences company founded in 2007 and headquartered in Billerica, Massachusetts. Originally incorporated as Digital Genomics, Inc., the company changed its name to Quanterix Corporation in August 2007 and went public in December 2017. Quanterix has established itself as a pioneer in ultra-sensitive protein detection technology, developing digital immunoassay platforms that enable researchers and clinicians to measure extremely low concentrations of proteins in biological samples. The company has undergone significant strategic transformation in recent years, focusing on neurology applications and building diagnostic testing capabilities, particularly for Alzheimer's disease biomarkers.